Clinical trial
A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer
NCT00298688 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00298688 |
|---|---|
| Title | A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer |
| Official title | Phase II Study of Iressa in Relapsed and Refractory Small Cell Lung Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Gefitinib |
| Enrollment | 56 |
| Start date | Sep 1, 2004 |
| Completion | Mar 1, 2007 |
| First posted | Mar 3, 2006 |
| Last update posted | Jun 12, 2008 |
| Countries | Denmark, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: